AMGN vs BIIB Stock Comparison: AI Score, Valuation, Performance and Upside
Amgen and Biogen are both established biotechnology companies working through legacy product transitions, but Amgen manages biosimilar competition across a diversified oncology, inflammation, and bone health portfolio while building an obesity pipeline, while Biogen navigates a declining multiple sclerosis franchise while working to grow its newer Alzheimer's disease treatment.
Amgen offers exposure to a diversified, established biotechnology platform with obesity drug pipeline upside, while Biogen offers a more concentrated, higher-risk bet on Alzheimer's treatment adoption offsetting its declining multiple sclerosis franchise. Consider whether you prefer Amgen's diversification or Biogen's more concentrated neuroscience turnaround potential.
BIIB holds the edge across 3 of 5 key metrics in this comparison. BIIB leads on both 1-year return (+67.40%) and forward P/E quality (13.21x vs 15.46x for AMGN), a relatively favorable combination of momentum and valuation. AMGN leads on both revenue growth (9.50%) and operating margin (35.55%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for BIIB (+8.11%) than for AMGN (+2.83%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to a diversified, established biotechnology platform across multiple disease areas
- Believe the emerging obesity drug pipeline offers meaningful long-term growth potential
- Are comfortable with ongoing biosimilar competition pressuring legacy product revenue
- Prefer a lower-concentration risk profile than a single-franchise turnaround story
- Are comfortable with higher risk tied to Alzheimer's drug commercial adoption uncertainty
- Believe deep neuroscience research expertise supports long-term pipeline potential
- Want to bet on a turnaround as the multiple sclerosis franchise declines
- See potential value in a company navigating a significant business transition
| Metric | AMGN | BIIB |
|---|---|---|
| AI scorei | 52.6 | 29.6 |
| AI ranki | #413 | #2281 |
| Latest closei | $460.73 | $249.65 |
| 1M returni | +8.76% | +9.94% |
| 3M returni | +18.86% | +20.06% |
| 6M returni | +33.06% | +31.89% |
| 1Y returni | +57.74% | +67.40% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | AMGN | BIIB |
|---|---|---|
| 1Y ago | $15.79K (+57.9%) started 2025-10-29 | $16.88K (+68.8%) started 2025-10-29 |
| 5Y ago | $28.13K (+181.3%) started 2021-11-01 | $9.17K (-8.3%) started 2021-11-01 |
| 10Y ago | $57.23K (+472.3%) started 2016-10-31 | $8.91K (-10.9%) started 2016-10-31 |
Hypothetical — past performance does not guarantee future results.
| Metric | AMGN | BIIB |
|---|---|---|
| Market capi | $204.01B | $32.28B |
| Trailing P/Ei | 23.42 | 38.74 |
| Forward P/Ei | 15.46 | 13.21 |
| Price/Salesi | 4.57 | 1.99 |
| EV/Revenuei | 6.49 | 3.92 |
| Analyst targeti | $388.03 | $236.22 |
| Target upsidei | +2.83% | +8.11% |
| Metric | AMGN | BIIB |
|---|---|---|
| Revenue growthi | 9.50% | 3.40% |
| Earnings growthi | 64.90% | -84.80% |
| EPS growthi | +64.90% | -84.80% |
| FCF margini | +22.69% | +12.63% |
| Operating margini | 35.55% | 25.06% |
| Profit margini | 22.95% | 8.32% |
| ROIC proxyi | 91.47% | 4.58% |
| Return on equityi | 91.47% | 4.58% |
| Dividend yieldi | 2.64% | N/A |
| Payout ratioi | 60.87% | 0.00% |
| Dividend growth streaki | No increase yet | N/A |
| Betai | 0.43 | 0.16 |
| Debt/equityi | 490.28 | 44.33 |
| Current ratioi | 1.37 | 1.86 |
| Quick ratioi | 0.95 | 0.94 |
Over the past year, AMGN and BIIB have moved moderately in the same direction (correlation of 0.50), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | AMGN | BIIB |
|---|---|---|---|
| 1Y | Growthi | +57.91% | +68.84% |
| CAGRi | +58.01% | +68.97% | |
| Volatilityi | 29.63% | 34.21% | |
| Sharpe ratioi | 1.55 | 1.58 | |
| Sortino ratioi | 2.44 | 2.47 | |
| Max drawdowni | 16.57% | 14.34% | |
| Current drawdowni | 0.00% | 1.65% | |
| Avg drawdowni | 5.96% | 4.26% | |
| Ulcer Indexi | 7.67% | 5.43% | |
| Max daily dropi | 10.08% | 8.17% | |
| Max wkly dropi | 15.03% | 12.37% | |
| 5Y | Growthi | +147.65% | -8.25% |
| CAGRi | +19.92% | -1.71% | |
| Volatilityi | 24.94% | 34.76% | |
| Sharpe ratioi | 0.68 | -0.02 | |
| Sortino ratioi | 1.02 | -0.02 | |
| Max drawdowni | 24.86% | 64.35% | |
| Current drawdowni | 0.00% | 21.51% | |
| Avg drawdowni | 8.19% | 31.20% | |
| Ulcer Indexi | 10.34% | 35.52% | |
| Max daily dropi | 10.08% | 8.17% | |
| Max wkly dropi | 15.03% | 13.62% | |
| 10Y | Growthi | +324.48% | -10.90% |
| CAGRi | +15.56% | -1.15% | |
| Volatilityi | 25.16% | 41.42% | |
| Sharpe ratioi | 0.52 | 0.06 | |
| Sortino ratioi | 0.78 | 0.10 | |
| Max drawdowni | 24.86% | 72.66% | |
| Current drawdowni | 0.00% | 39.80% | |
| Avg drawdowni | 7.88% | 35.16% | |
| Ulcer Indexi | 9.76% | 39.47% | |
| Max daily dropi | 10.08% | 29.23% | |
| Max wkly dropi | 15.03% | 34.30% |
| Category | AMGN | BIIB |
|---|---|---|
| Company | Amgen Inc. | Biogen Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Core business | A global biotechnology company with an established portfolio spanning oncology, inflammation, and bone health treatments, alongside a growing obesity drug pipeline, working to manage biosimilar competition on legacy products. | A biotechnology company focused on neuroscience treatments, including therapies for multiple sclerosis and a newer Alzheimer's disease treatment, working to rebuild pipeline momentum as legacy multiple sclerosis products face competition. |
| Investor focus | Growth of newer drugs including obesity pipeline candidates, biosimilar competition trends on legacy products, and dividend sustainability given the maturity of its established portfolio. | Alzheimer's drug commercial adoption and revenue trajectory, legacy multiple sclerosis franchise decline trends, and pipeline progress across other neuroscience disease areas. |
- Established biotechnology platform with deep expertise across oncology, inflammation, and bone health treatment categories
- Emerging obesity drug pipeline provides exposure to one of the fastest-growing pharmaceutical categories
- Long operating history and manufacturing scale support efficient production and distribution of biologic therapies
- Deep expertise in neuroscience research provides a differentiated position in a complex, high-barrier therapeutic area
- Newer Alzheimer's disease treatment represents a novel growth driver in a large, underserved patient population
- Established multiple sclerosis franchise, while declining, continues to generate meaningful cash flow to fund pipeline investment
- Legacy biologic products face ongoing biosimilar competition that pressures revenue over time
- Obesity drug pipeline remains in earlier competitive stages relative to some established rivals in that category
- Biotechnology manufacturing and pipeline development require sustained, significant research and development investment
- Legacy multiple sclerosis products face declining revenue as competition and generic alternatives take share
- Alzheimer's drug commercial adoption has been slower and more uncertain than some initial expectations
- Pipeline productivity must improve to offset the ongoing decline of its historically core multiple sclerosis business
Compare more than two at a time
This page is a fixed writeup on AMGN and BIIB. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside AMGN and BIIB, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.